Endsulin

Endsulin is a private, early-stage biotechnology company based in Madison, Wisconsin developing a liver-directed gene therapy for type 1 diabetes mellitus. Its approach is designed to reprogram a fraction of liver cells to produce and regulate insulin in a glucose-responsive manner, with the goal of providing long-term or potentially life-long insulin independence after a single outpatient infusion. The company’s technology is based on decades of research by founder Hans Sollinger at the University of Wisconsin-Madison and centers on patented gene constructs including GIRE and TA1m. Public materials indicate encouraging preclinical mouse data and describe planned next-stage translational work in diabetic dogs before human studies. Endsulin appears focused primarily on a single lead genetic medicine rather than a broad multi-asset pipeline.